nevirapine has been researched along with EBV Infections in 1 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slyker, JA | 1 |
| Casper, C | 1 |
| Tapia, K | 1 |
| Richardson, B | 1 |
| Bunts, L | 1 |
| Huang, ML | 1 |
| Wamalwa, D | 1 |
| Benki-Nugent, S | 1 |
| John-Stewart, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)[NCT00428116] | 140 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to DSMB recommended termination because TI was safe but not durable.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender. (NCT00428116)
Timeframe: 18 months of post-randomization follow-up
| Intervention | z-score (Median) | |
|---|---|---|
| WAZ (z-score) | HAZ (z-score) | |
| Continued HAART | -0.57 | -1.04 |
| Interrupted HAART | -0.17 | -0.78 |
severe adverse events including death, pneumonia, diarrhea, and other adverse events (NCT00428116)
Timeframe: 18 months post-randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Severe adverse events | Pneumonia | Diarrhea | Death | |
| Continue HAART | 2 | 4 | 7 | 1 |
| Interrupted HAART | 1 | 3 | 12 | 0 |
1 other study available for nevirapine and EBV Infections
| Article | Year |
|---|---|
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; I | 2014 |